Patent EP0500289A1 successfully refreshed from Google Patents.
US5531791A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Composition for repair of defects in osseous tissues, method of making, and prosthesis
Assignee: Lifenet Health
•
Filing: 1993-07-23
•
Granted: 1996-07-02
•
Expires: 2013-07-23
Abstract
Abstract A biocompatible collagen/demineralized human bone composite material, method for making the same, and prostheses employing the same are disclosed, wherein the composite material may be formulated into a fluid injectable, gel or rehydratable freeze dried paste. The resultant products can be used either alone or combined with a prosthetic device as an osteoinductive/osteoconductive material.
Inventors
- 👤 Lloyd Wolfinbarger, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 01:58
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/38; A61L27/3839; A61L27/3843; A61L27/3847; A61F; A61F2/00; A61F2/02; A61F2/28; A61L27/14; A61L27/22; A61L27/24; A61L27/26; A61L27/3604; A61L27/3608; A61L27/3641; A61L27/3645; A61L27/365; A61L27/40; A61L27/44; A61L27/46; A61F2/30; A61F2002/30001; A61F2002/30316; A61F2002/30535; A61F2002/30581; A61F2002/30583; A61F2210/00; A61F2210/0085; A61F2310/00; A61F2310/00005; A61F2310/00365; A61L2430/00; A61L2430/02
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
26 words
A non-immunogenic composition for the promotion of allogenic bone growth and repair in an individual, comprising: demineralized human bone powder, and type-I telopeptide containing human collagen.
Claim 2
Dependent Claim
26 words
A non-immunogenic composition for the promotion of allogenic bone growth and repair in an individual, comprising: demineralized human bone powder, and type-I telopeptide containing human collagen.
Claim 3
Dependent Claim
43 words
A non-immunogenic composition for the promotion of allogenic bone growth and repair in an individual, comprising: demineralized human bone powder, and type-I telopeptide containing human collagen, wherein said human bone powder and said human collagen are derived from the same human cadaver source.
Claim 4
Dependent Claim
43 words
A non-immunogenic composition for the promotion of allogenic bone growth and repair in an individual, comprising: demineralized human bone powder, and type-I telopeptide containing human collagen, wherein said human bone powder and said human collagen are derived from the same human cadaver source.
Claim 5
Dependent Claim
19 words
The non-immunogenic composition of claim 2, wherein said human collagen is derived from tendons and ligaments of said human.
Claim 6
Dependent Claim
24 words
The non-immunogenic composition of claim 2, wherein said type-I telopeptide containing human collagen comprises about 0.25 to 40.00 weight percent of said non-immunogenic composition.
Claim 7
Dependent Claim
55 words
The non-immunogenic composition of claim 2, wherein said type-I telopeptide containing human collagen is produced by the process, comprising: extracting said collagen from said human cadaver source in dilute acid to produce extracted collagen; precipitating said extracted collagen from said acid solution to produce precipitated collagen; and washing said precipitated collagen to form washed collagen.
Claim 8
Dependent Claim
17 words
The non-immunogenic composition of claim 5, wherein said dilute acid comprises one or more dilute organic acids.
Claim 9
Dependent Claim
19 words
The non-immunogenic composition of claim 6, wherein said dilute organic acid has a pH of from 3 to 4.
Claim 10
Dependent Claim
35 words
The non-immunogenic composition of claim 6, wherein said dilute organic acid is one or more member selected from the group consisting of: acetic acid, lactic acid, malic acid, citric acid, glutaric acid, and proprionic acid.
Claim 11
Dependent Claim
14 words
The non-immunogenic composition of claim 8, wherein said dilute organic acid is acetic acid.
Claim 12
Dependent Claim
34 words
The non-immunogenic composition of claim 5, wherein said process further comprises the steps of: resolubilizing said washed collagen to form resolubilized collagen, and dialyzing said resolubilized collagen against isotonic saline to form dialyzed collagen.
Claim 13
Dependent Claim
22 words
The non-immunogenic composition of claim 10, wherein said steps of washing, resolubilizing, and dialyzing, are cyclically repeated from 2 to 6 times.
Claim 14
Dependent Claim
23 words
The non-immunogenic composition of claim 11, wherein said demineralized human bone powder comprises about 20 to 90 weight percent of said non-immunogenic composition.
Claim 15
Dependent Claim
23 words
The non-immunogenic composition of claim 12, wherein said demineralized human bone powder comprises about 30 to 50 weight percent of said non-immunogenic composition.
Claim 16
Dependent Claim
25 words
The non-immunogenic composition of claim 13, wherein said demineralized human bone powder has a particle size of from about 125 microns to about 2 millimeters.
Claim 17
Dependent Claim
25 words
The non-immunogenic composition of claim 14, wherein said demineralized human bone powder has a particle size of from about 125 microns to about 500 microns.
Claim 18
Dependent Claim
25 words
The non-immunogenic composition of claim 14, wherein said demineralized human bone powder has a particle size of from about 250 microns to about 710 microns.
Claim 19
Dependent Claim
24 words
The non-immunogenic composition of claim 14, wherein said demineralized bone powder has a particle size of from about 710 microns to about 2 millimeters.
Claim 20
Dependent Claim
21 words
The non-immunogenic composition of claim 2, wherein said non-immunogenic composition is flowable and injectable, and is a gel or a paste.
Claim 21
Dependent Claim
50 words
The non-immunogenic composition of claim 2, further comprising: one or more elements selected from the group consisting of: a bioactive compound, an antibiotic, an antiviral agent, an antitumor agent, an immunosuppressant agent, a permeation enhancer, a nucleic acid, a mesenchymal element, a gelation enhancing compound and autogenously derived osteoblast cells.
Claim 22
Dependent Claim
37 words
The non-immunogenic composition of claim 19, wherein said bioactive compound is one or more members selected from the group consisting of: bone morphogenetic protein, transforming growth factor β, fibroblast growth factor, insulin, and platelet derived growth factor.
Claim 23
Dependent Claim
11 words
The non-immunogenic composition of claim 19, wherein said antibiotic is penicillin.
Claim 24
Dependent Claim
18 words
The non-immunogenic composition of claim 19, wherein said antiviral agent is a detergent or a peroxide generating agent.
Claim 25
Dependent Claim
29 words
The immunogenic composition of claim 22, wherein said detergent is one or more members selected from the group consisting of: Triton X-100, sodium dodecyl sulfate, Nonidet P-40, and Brij-35.
Claim 26
Dependent Claim
15 words
The non-immunogenic composition of claim 19, wherein said immunosuppressant agent is bovine intestinal choline phosphatase.
Claim 27
Dependent Claim
17 words
The non-immunogenic composition of claim 19, wherein said permeation enhancer is one or more fatty acid esters.
Claim 28
Dependent Claim
28 words
The non-immunogenic composition of claim 25, wherein said fatty acid ester is a mono ester of polyethylene glycol selected from the group consisting of: laureate, myristate and stearate.
Claim 29
Dependent Claim
28 words
The non-immunogenic composition of claim 19, wherein said gelation enhancing compound is a glycosanine glycan selected from the group consisting of: hyaluronic acid, chondroitin sulfate and dermatin sulfate.
References Cited (Backward Citations)
US3742955A
Cited
US3810473A
Cited
US4223360A
Cited
US3949073A
Cited
US4488911A
Cited
US4140537A
Cited
CA1142430A
Cited
US4412947A
Cited
EP0030583A1
Cited
US4314380A
Cited
US4394370A
Cited
JPS5858041A
Cited
US4430760A
Cited
US4424208A
Cited
US4440750A
Cited
US4582640A
Cited
US4578067A
Cited
US4434094A
Cited
US4515637A
Cited
US4789663A
Cited
US4843063A
Cited
US4627982A
Cited
US4810691A
Cited
US4774228A
Cited
US4774322A
Cited
US4863475A
Cited
US4557764A
Cited
US4563350A
Cited
US5001169A
Cited
US4888366A
Cited
US4725671A
Cited
US4689399A
Cited
US4655980A
Cited
US4600533A
Cited
US4687763A
Cited
US4642117A
Cited
US5246457A
Cited
US4795467A
Cited
US4992226A
Cited
US4806523A
Cited
US5008240A
Cited
US4776890A
Cited
US4774227A
Cited
US4803075A
Cited
US5071351A
Cited
US5035715A
Cited
US4865602A
Cited
US5123925A
Cited
US4816442A
Cited
US4863732A
Cited
US5266683A
Cited
US5250302A
Cited
US5258494A
Cited
US4968590A
Cited
US5110604A
Cited
US5219576A
Cited
US4950483A
Cited
US5024841A
Cited
US5011691A
Cited
US5207710A
Cited
US5108436A
Cited
US5258029A
Cited
US5162430A
Cited
US5264214A
Cited
US5171574A
Cited
US5162114A
Cited
US5073373A
Cited
EP0495284A1
Cited
WO1992018142A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-07-02 | 2000-01-01 | 2000-07-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-07-02 | 2004-01-01 | 2004-07-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-07-02 | 2008-01-01 | 2008-07-02 | $7700.00 | Window Closed / Lapsed |